Gilead’s HIV Shot Reduced Infections By 96% In Late-Stage Trial—Beating Daily Pill
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...
Twice-yearly injection reduced HIV infections by 96 percent, company says
Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...
Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill
A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than ...
WUNC3d
Ukraine keeps up the fight against HIV while fighting a war
Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...
KUAR5d
This preventive drug could be a 'game changer" in ending the HIV epidemic
In newly released data, lenacapavir, administered via a twice-yearly injection, has shown remarkable effectiveness at ...
AOL9d
Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
Gilead’s HIV-prevention drug cut infections by 96%, boosting stock
Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, ...
STAT10d
Gilead’s twice-yearly antiviral protects against HIV infection in second large trial
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate ...
The Montgomery Advertiser on MSN2d
HIV stigma is on the decline for the first time in five years, new study finds
HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...
MarketWatch1d
Gilead’s HIV-prevention drug cut infections by 96%, boosting stock
Gilead Sciences Inc.’s stock climbed 3% early Thursday after the company said its twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, building the case for ...
CNN10d
Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill
A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.